| Abbreviation | Meaning | Abbreviation | Meaning |
| 5-FU | 5-fluorouracil | mAbs | monoclonal antibodies |
| ACT | adoptive cell therapies | MAIT | mucosal-associated invariant T |
| ADCC | antibody-dependent cell-mediated cytotoxicity | MANAs | mutation-associated neoantigens |
| APCs | antigen-presenting cells | mCRC | metastatic CRC |
| bsAbs | bispecific antibodies | MDSCs | myeloid-derived suppressor cells |
| bsTCEs | T cell-engaging bsAbs | miRNA | microRNA |
| CAAs | cancer-associated antigens | MMR | mismatch repair |
| CAR-T cell | chimeric antigen receptor T cell | MSI | microsatellite instable |
| CEA | carcinoembryonic antigen | MSI-H | MSI-high |
| cGAS | cyclic GMP-AMP synthase | MSS | microsatellite stable |
| CIMP | CpG island methylator phenotype | Nbs | nanobodies |
| CIN | chromosomal instability | NDV | Newcastle disease virus |
| CRC | colorectal cancer | NK | natural killer |
| ctDNA | circulating tumor DNA | NKG2 | Natural Killer Group 2 |
| CTLA-4 | cytotoxic T-lymphocyte-associated protein 4 | NLR | neutrophil-to-lymphocyte |
| DCs | dendritic cells | NSCLC | non-small-cell lung cancer |
| dMMR | MMR deficiency | PD-1 | programmed cell death protein 1 |
| DR5 | death receptor 5 | PD-L1 | programmed cell death ligand 1 |
| dsDNA | double stranded DNA | PFS | progression-free survival |
| EpCAM/CD326 | epithelial cell adhesion molecule | pMMR | proficient MMR |
| EphA2 | ephrin type-A receptor 2 | PtdSer | phosphatidyl serine |
| FLT3L | Flt-3 Ligand | SNPs | single-nucleotide polymorphisms |
| Gal-9 | galectin-9 | STING | stimulator of interferon genes |
| GUCY2C | guanylyl cyclase C | STRs | short tandem repeats |
| HAVCR2 | hepatitis A virus cellular receptor 2 | T regs | regulatory T cells |
| HLA | human leukocyte antigen | TAAs | tumor-associated antigens |
| HMGB1 | high mobility group box 1 protein | TAG | tumor-associated glycoprotein |
| ICB | immune checkpoint blockade | TAMs | tumor-associated macrophages |
| IFNs | interferons | TCR | T cell receptor |
| ILs | interleukins | TGFβR2 | transforming growth factor β receptor type 2 |
| IMiDs | immunomodulatory drugs | TIL | tumor-infiltrating lymphocyte |
| IT | immunotherapy | TIM-3 | T cell immunoglobulin- and mucin-domain-containing-3 |
| LAG-3 | lymphocyte activation gene-3 | TMB-H | high tumor mutational burden |
| lncRNA | long non-coding RNA | TME | tumor microenvironment |